Jazz Pharmaceuticals Retained Earnings (Accumulated Deficit) 2010-2025 | JAZZ
Jazz Pharmaceuticals retained earnings (accumulated deficit) for the quarter ending March 31, 2025 were $1.035B, a 19.75% increase year-over-year.
- Jazz Pharmaceuticals retained earnings (accumulated deficit) for 2024 were $1.128B, a 28.29% increase from 2023.
- Jazz Pharmaceuticals retained earnings (accumulated deficit) for 2023 were $0.879B, a 19.76% increase from 2022.
- Jazz Pharmaceuticals retained earnings (accumulated deficit) for 2022 were $0.734B, a 11.63% decline from 2021.